NEW YORK (GenomeWeb) – Qiagen announced today that it has partnered with Mirati Therapeutics to co-develop and commercialize a companion diagnostic for Mirati's glesatinib, a targeted therapy under development for the treatment of non-small cell lung cancer.

The diagnostic is intended to guide physicians in whether or not to prescribe glesatinib to NSCLC patients by detecting RNA biomarkers produced by exon 14 skipping mutations of the MET gene.

 Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.